XFORX4 Pharmaceuticals, Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $3.51 · now $3.51 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, XFOR has typically landed between $1.99 and $5.32 — a range of −43.3% to +51.6% from the issuance price $3.51.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

2,194 overlapping 1 month windows · 2017-11-162026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($3.51) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where XFOR has typically landed a month from the 2026-09-16 close of $3.51 — the range is history, not a prediction.

$1.99worst · -43.3%$5.32best · +51.6%
  • now $3.51 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $3.29 (-6.1%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $2.79$3.8
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $1.99$5.32
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 2,194 windows spanning 2017-11-16 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2018-06-27−86.6%−86.6%+0.0%
2018-06-26−86.1%−86.1%+0.0%
2018-06-22−85.6%−85.6%+0.0%
3 best
2018-10-30+194.7%−12.1%+194.7%
2018-10-29+194.4%−7.9%+194.4%
2018-11-09+186.9%−15.3%+186.9%

2,194 overlapping windows · 2017-11-162026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~9 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
33%
−1.1%
n=9
Feb
56%
+0.8%
n=9
Mar
56%
+8.5%
n=9
Apr
22%
−2.5%
n=9
May
33%
−3.0%
n=9
Jun
22%
−23.0%
n=9
Jul
22%
−5.2%
n=9
Aug
44%
+6.9%
n=9
Sep
22%
−1.6%
n=9
Oct
25%
−8.4%
n=8
Nov
25%
+16.1%
n=8
Dec
44%
−5.0%
n=9

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$5$22026-08-12: 2 insider sales, $320K — Craig Adam R, Volpone John2026-06-30: 1 insider sale, $36K — KIRSKE DAVID2026-05-12: 1 insider sale, $73K — KIRSKE DAVID2025-10-23: 1 insider purchase, $250K — Craig Adam R2025-10: 1 open-market purchase, $250K2026-05: 1 open-market sale, $73K2026-06: 1 open-market sale, $36K2026-08: 2 open-market sales, $320K↑ buys↓ salesdirector Craig Adam R — Sale on 2026-08-12, filed 1 day after the tradeofficer Volpone John — Sale on 2026-08-12, filed 1 day after the tradeofficer KIRSKE DAVID — Sale on 2026-06-30, filed 1 day after the tradeofficer KIRSKE DAVID — Sale on 2026-05-12, filed 1 day after the tradedirector Craig Adam R — Purchase on 2025-10-23, filed 4 days after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-08-12Craig Adam RdirectorSale47,436 @ $4.44$211K−12.6% of holding−17.4%not yet — horizon still open328,651Form 4 · filed 1 day after the trade
2026-08-12Volpone JohnofficerSale24,576 @ $4.44$109K−8.5% of holding−17.4%not yet — horizon still open265,305Form 4 · filed 1 day after the trade
2026-06-30KIRSKE DAVIDofficerSale8,543 @ $4.26$36K−4.8% of holding−13.7%not yet — horizon still open167,750Form 4 · filed 1 day after the trade
2026-05-12KIRSKE DAVIDofficerSale16,961 @ $4.29$73K−8.8% of holding−10.5%not yet — horizon still open176,293Form 4 · filed 1 day after the trade
2025-10-23Craig Adam RdirectorPurchase86,206 @ $2.90$250K+29.7% of holding+23.3%+29.2%376,087Form 4 · filed 4 days after the trade
2025-05-16Baldry MarkofficerPurchase1,032 @ $2.48$3K+4.2% of holding−6.7%+12.7%25,337Form 4 · filed 4 days after the trade
2025-01-24Ragan PauladirectorSale76,473 @ $0.45$35K−6.6% of holding−6.4%−90.5%1,087,386Form 4 · filed 3 days after the trade
2025-01-24Mostafa Adam S.officerSale74,773 @ $0.45$34K−100.0% of holding−6.4%−90.5%0Form 4 · filed 3 days after the trade
2025-01-24Baldry MarkofficerSale29,159 @ $0.45$13K−23.7% of holding−6.4%−90.5%94,123Form 4 · filed 3 days after the trade
2025-01-24DiBiase MaryofficerSale22,258 @ $0.45$10K−4.3% of holding−6.4%−90.5%490,980Form 4 · filed 3 days after the trade
2025-01-24Arbet-Engels ChristopheofficerSale11,624 @ $0.45$5K−45.0% of holding−6.4%−90.5%14,207Form 4 · filed 3 days after the trade
2024-11-15Baldry MarkofficerPurchase13,404 @ $0.34$5K+11.6% of holding+79.8%−77.3%129,173Form 4 · filed 91 days after the trade
2024-05-17Baldry MarkofficerPurchase21,646 @ $0.68$15K+23.0% of holding+0.4%−67.8%115,769Form 4 · filed 273 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

34 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-07-01Gold KellydirectorAward / grant110,000110,000Form 4
2026-01-01Stewart MurraydirectorAward / grant110,0000Form 4
2026-01-01WYZGA MICHAEL SdirectorAward / grant110,0000Form 4
2026-01-01de Craecker FrancoisedirectorAward / grant110,0000Form 4
2026-01-01Bridger GarydirectorAward / grant110,0000Form 4
2025-10-29Craig Adam RdirectorAward / grant2,329,1542,329,154Form 4
2025-10-29Volpone JohnofficerAward / grant2,329,1542,329,154Form 4
2025-10-29KIRSKE DAVIDofficerAward / grant1,552,7691,552,769Form 4
2025-08-14Volpone JohnofficerAward / grant529,201529,201Form 4
2025-08-14Volpone JohnofficerAward / grant289,881289,881Form 4
2025-08-14KIRSKE DAVIDofficerAward / grant193,254193,254Form 4
2025-08-14Craig Adam RdirectorAward / grant529,201529,201Form 4
2025-08-14KIRSKE DAVIDofficerAward / grant352,800352,800Form 4
2025-08-14Craig Adam RdirectorAward / grant289,881289,881Form 4
2025-08-12Volpone JohnofficerAward / grant1,609,8731,609,873Form 4
2025-08-12KIRSKE DAVIDofficerAward / grant1,073,2491,073,249Form 4
2025-08-12Craig Adam RdirectorAward / grant1,609,8731,609,873Form 4
2025-06-09MCGIRR DAVID W JdirectorAward / grant1,5004,722Form 4
2025-06-09WYZGA MICHAEL SdirectorAward / grant1,5005,555Form 4
2025-06-09Woods KeithdirectorAward / grant1,5006,000Form 4
2025-06-09Stewart MurraydirectorAward / grant1,5007,883Form 4
2025-06-09Bridger GarydirectorAward / grant1,5004,722Form 4
2025-06-09de Craecker FrancoisedirectorAward / grant1,5004,722Form 4
2025-05-20Thoren Natasha FayofficerAward / grant3,3339,462Form 4
2025-02-12Arbet-Engels ChristopheofficerAward / grant850,000864,207Form 4
2025-02-12Ragan PauladirectorAward / grant2,250,0003,337,386Form 4
2025-02-12Baldry MarkofficerAward / grant600,000729,173Form 4
2025-02-12DiBiase MaryofficerAward / grant650,0001,140,980Form 4
2025-02-12Mostafa Adam S.officerAward / grant850,000850,000Form 4
2025-01-23DiBiase MaryofficerAward / grant61,178513,238Form 4
2025-01-23Baldry MarkofficerAward / grant74,773123,282Form 4
2025-01-23Ragan PauladirectorAward / grant169,9401,163,859Form 4
2025-01-23Arbet-Engels ChristopheofficerAward / grant25,83125,831Form 4
2025-01-23Mostafa Adam S.officerAward / grant74,77374,773Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.